Introduction
Chronic myeloproliferative diseases (CMPDs) are characterized by the overproduction of one or more myeloid lineages in the bone marrow, while the maturation of the myeloid cells is not significantly affected. As a consequence, granulocytes, red blood cells and/or platelets can be increased in the peripheral blood, and this is frequently associated with splenomegaly and hepatomegaly. CMPDs are further classified as chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IM). In addition, systemic mastocytosis (SM), characterized by abnormal proliferation of mast cells is a related disease. These specific disease entities can, however, be difficult to distinguish, and recent work has shown that there is also an overlap at the molecular level. Here, we discuss our current insights in the molecular genetics of CMPDs, and propose a methodology to further screen for new mutations in protein tyrosine kinase genes.
Chromosomal translocations in CMPD
Early insights into the molecular cause of these hematological diseases came from studies on CML, where Peter Nowell and David Hungerford described the presence of an abnormal chromosome, the so-called Philadelphia (Ph) chromosome. Further molecular analysis revealed that the Ph chromosome was the result of a balanced chromosomal translocation generating the BCR-ABL1 (previously named BCR-ABL) fusion gene ( Figure 1 ). 1 Now, 20 years later, these molecular insights have been translated into diagnostic tests to identify leukemia patients with BCR-ABL1 positive CML, and, most importantly, into targeted therapy. 2 Unlike CML, in which the t(9;22) or cytogenetic variants characterize almost all the cases, chromosomal abnormalities are relatively rare in the other CMPDs, but a subset of CEL cases Figure 1 Overview of the protein structure of the most common aberrant protein tyrosine kinases involved in the pathogenesis of CMPDs. Initiation of ABL1, FGFR1 and PDGFRb kinase activity is caused by kinase oligomerization via the BCR-, ZNF198-and ETV6-fusion partners. A similar mode of action was suggested for PCM1-JAK2. The activation mechanism of FIP1L1-PDGFRa remains to be determined, but no oligomerization domain has been identified in FIP1L1. In JAK2, the V617F mutation disrupts the negative regulation by the pseudo-kinase domain, resulting in a constitutively active kinase. In KIT, the D816V mutation is located in the catalytic domain of the kinase. Abbreviations: CC, coiled-coil; S/T kinase. Serine/ Threonine kinase; SH, Src homology; PNT, Pointed domain; TM, Transmembrane domain; JM, Juxtamembrane domain; FERM, 4.1-ezrin-radixin-moesin domain. Note that the full PCM1-JAK2 fusion protein is larger than indicated in this figure (should be larger than BCR-ABL1).
harbors chromosomal translocations involving the PDGFRB gene at 5q33 (also referred to as CMML with eosinophilia) or the FGFR1 gene at 8p11 (also referred to as 8p11 myeloproliferative syndrome or stem cell leukemia-lymphoma syndrome). 3 A variety of chromosomal translocations have been described that involve these genes (Table 1 ). Similar to the Ph chromosome, these translocations result in the generation of in-frame fusion genes encoding activated forms of the PDGFRb and FGFR1 tyrosine kinases. The most common fusions are ETV6-PDGFRB and ZNF198-FGFR1 (Figure 1 ), but the list of fusion partners of PDGFRB and FGFR1 is continuously expanding, putting these genes among the oncogenes with the highest number of fusion partners ( Figure 1 , Table 1 ). More recently, several patients with t(8;9)(p22;p24) and with variable CMPD entities or acute leukemias were described. This translocation results in the generation of a PCM1-JAK2 fusion gene ( Figure 1 , Table 1 ). [4] [5] [6] Similar to ABL1, PDGFRB and FGFR1 fusions, PCM1-JAK2 is believed to encode a constitutively activated tyrosine kinase that activates proliferation and survival pathways.
Genetic defects in patients with apparent normal cytogenetics
While CML and some CEL cases are characterized by chromosomal translocations involving a number of protein tyrosine kinase genes, chromosomal abnormalities are not common in the remaining CMPDs. This makes a genetic analysis of these cases more challenging, since chromosomal abnormalities directly provide information about possible candidate genes located in the affected chromosomal regions. However, based on the common proliferative defect in all CMPDs, and since activated tyrosine kinases were known to cause abnormal proliferation of myeloid cells, and were known to be involved in the pathogenesis of a subgroup of CMPDs, it seemed plausible that other tyrosine kinase genes could be affected in the uncharacterized cases. This hypothesis is supported by the c-KIT D816V mutation involved in systemic mastocytosis (SM), and by the recently identified FIP1L1-PDGFRA fusion gene and JAK2 V617F mutation in CEL and PV, ET and IM respectively. Table 1 Overview of the chromosomal aberrations and mutations involving tyrosine kinase genes in CMPD 
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CEL
The HUGO gene symbol is provided for all genes; previous gene nomenclature: ABL1 (ABL), CEP1 (CEP110), ETV6 (TEL), CCDC6 (H4), TRIP11(CEV14), SPECC1(HCMOGT1), RABEP1(RABAPTIN5), TRIM24 (TIF1), LOC113386 (HERV-K). het, heterozygous mutation; hom, homozygous mutation. *The JAK2 mutation is most common in PV, ET and IM, but has now also been identified in other CMPDs, including some cases with CNL, CEL, and atypical CML.
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Cryptic chromosomal deletion in CEL CEL is closely related to the hypereosinophilic syndrome (HES), but is distinguished from it based on the evidence of clonality and/or on the presence of increased blasts. However, besides the cases with translocations involving PDGFRB or FGFR1 or other rare translocations (for example PCM1-JAK2, BCR-PDGFRA), [4] [5] [6] 14 most other CEL cases present with an apparent normal karyotype. As a consequence, the clonal origin of most CEL cases remained unrecognized and these cases were frequently misclassified as 'idiopathic' HES. The discovery of a cryptic deletion on 4q12, associated with the FIP1L1-PDGFRA fusion gene (Figure 1, Table 1) , 8 now makes a correct diagnosis possible by detection of the deletion by FISH or detection of the fusion transcript by RT-PCR. The chromosomal deletion that generates the FIP1L1-PDGFRA fusion gene is only 800 kb in size, explaining why this abnormality is not detectable by standard cytogenetics and remained unrecognized until recently. 8 Several studies have addressed the involvement of FIP1L1-PDGFRA in the pathogenesis of CEL, which confirm that approximately 20-50% of the CEL/HES cases express this fusion gene, and highlight some remarkable features of this subentity. 8, [15] [16] [17] [18] First of all, the FIP1L1-PDGFRA fusion is almost exclusively found in males (490% males), 8, [15] [16] [17] [18] and corresponds very well with elevated serum tryptase levels. 18 Second, the presence of the fusion gene is a positive predictor for response to low doses of imatinib (100 mg per day), which is explained by fact that FIP1L1-PDGFRa is 4100-fold more sensitive to imatinib compared to BCR-ABL1. 8, 19 In contrast to CML, in which only a minority of the BCR-ABL1 positive patients achieve a molecular remission, most patients with FIP1L1-PDGFRA positive CEL achieve complete molecular remission, with the fusion gene not longer detectable by sensitive RT-PCR methods. 17, 20 The development of resistance to imatinib does not seem to be a major problem in CEL, which may be explained by the extreme sensitivity of FIP1L1-PDGFRa to imatinib. To date, only two patients have been described who developed resistance due to a T674I mutation in the kinase domain of PDGFRa, 8, 21 and a variant small molecule inhibitor (PKC412) was already identified that can overcome this resistance. 22 Although we know that FIP1L1-PDGFRA positive patients respond well to imatinib treatment, it is not recommended to treat only these patients with imatinib, since also some FIP1L1-PDGFRA negative CEL patients were reported to respond to imatinib therapy (Table 1) . 8, 15, 17 The reason for this response remains unknown, but it indicates that a short trial of imatinib in all CEL patients should be considered, given the rapid and complete response of these patients to imatinib treatment, and the relatively bad response to classical treatment. 17, 18 JAK2 V617F mutation in PV, ET, IM Already for a long time, defects in the erythropoietin receptor (EPOR), were known to be the cause of familial forms of PV, but were not detected in sporadic forms of PV or other CMPDs. 23 These mutations in the EPOR lead to constitutive signaling of the receptor, including activation of JAK2, a tyrosine kinase associated with the EPOR. 24 In addition, one of the hallmarks of cells derived from PV and ET patients is their ability to generate erythroid colonies in the absence of EPO, implicating constitutive signaling of the EPOR in the pathogenesis of this subset of CMPDs. It is thus not completely surprising that a mutation in JAK2 itself has now been identified in PV, ET and IM. Five independent studies reported on the identification of a single V617F mutation in JAK2 in most patients with PV (60-90%), as well as in a significant subset (30-50%) of ET and IM (Table 1) . [9] [10] [11] [12] [13] The V617F mutation occurs in the pseudokinase domain of JAK2, previously illustrated to be a negative regulator of the kinase activity of JAK2 (Figure 1) . 25 In agreement with this, JAK2(V617F) behaves as a constitutively activated tyrosine kinase when expressed in cell lines, 10, 12 although its activity may be most pronounced in association with the EPO receptor. 11, 12 The JAK2 mutation is a common mutation in PV, ET and IM patients, but has now also been detected in cases with other CMPDs and in a low percentage of AML patients. [26] [27] [28] All these patients, without any exception so far, harbor the same point mutation (GTC4TTC, V617F), and surprisingly, a significant fraction of the patients are homozygous for the mutant allele. Extensive work has confirmed that this is not due to deletion of the wild type allele, but rather due to mitotic recombination, leading to the exchange of the 9p24 chromosomal region carrying the wild type JAK2 allele with the 9p24 region carrying the mutated allele (uniparental disomy).
11,12 As a consequence, homozygous patients carry two copies of the mutated JAK2 allele in the absence of the wild-type JAK2, which is believed to provide the cells with an additional proliferation and/or survival advantage. 10 It has also been shown that CMPD patients with the V617F mutation have a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage and thrombosis) than patients with wild-type JAK2.
11
KIT D816V mutation in SM
Patients with SM suffer from an accumulation of mast cells in one or more extracuteous organs, most often the gastrointestinal tract, spleen and bone marrow. 29 The KIT protein is a transmembrane receptor with intrinsic tyrosine kinase activity essential for mast cell development. Under normal circumstances, binding of stem cell factor to the receptor is required for activation of its kinase activity. In sporadic adult SM, it has been shown that mast cells often carry the D816V mutation in the activation loop of the kinase domain of KIT. 7 This mutation causes constitutive KIT activation and is believed to contribute to the abnormal proliferation and survival of these neoplastic cells. While kinase activity of wild-type KIT is inhibited by imatinib, this drug has no activity against the D816V mutant, but the observation that PKC412 and AMN107 counteract kinase activity of KIT D816V suggest that these inhibitors could be used for targeted therapy of SM.
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Detection of tyrosine kinase aberrations in CMPD Based on our insights in the molecular defects of CMPDs, a variety of diagnostic tools were developed to identify patients with any of these aberrations, and to follow the course of the disease during and after treatment. The detection of the BCR-ABL1 fusion gene can be done at the chromosome level by FISH analysis or at the RNA level by RT-PCR to detect the BCR-ABL1 transcript. Although the latter method is more sensitive, it may miss some of the variant BCR-ABL1 fusions, 33 and it cannot detect ABL1 rearrangements other than the BCR-ABL1 fusion. In contrast, FISH should be able to detect all aberrations of ABL1, regardless the type of fusion and regardless the fusion partner. This is important for diagnosis, since several variant BCR-ABL1 fusions as well as another fusion partner of ABL1 (namely ETV6) have been described. For follow-up during therapy, quantitative RT-PCR is currently the most reliable technique to follow copy number changes, given that the RNA is of good quality and that the correct control gene is used. 34 The detection of the FIP1L1-PDGFRA fusion gene can be performed by FISH, or by RT-PCR. 8, [16] [17] [18] Since there are also cases with the BCR-PDGFRA fusion gene, 14 detection of rearrangement of PDGFRA by FISH remains a valuable test at diagnosis. FISH can be accompanied by RT-PCR analysis to detect the type of FIP1L1-PDGFRA fusion transcript. Unlike BCR-ABL1, where most CML patients harbor the b3a2 or b2a2 fusion transcript, the breakpoints in FIP1L1 are highly variable, and as a consequence the FIP1L1-PDGFRA transcripts display the same variability. 8 This has important consequences for the detection of the FIP1L1-PDGFRA fusion transcript by quantitative RT-PCR. Quantitative PCR requires the amplification of a relatively short fragment, and with the heterogeneity of the fusion transcripts, it is not possible to design a single amplicon that would allow the quantification of all FIP1L1-PDGFRA transcripts from different patients. Further work is required to solve this problem, and it will be interesting to test if quantification of 3' PDGFRA expression is a good alternative for the quantification of FIP1L1-PDGFRA.
Finally, since the JAK2 V617F mutation is not accompanied by a chromosomal abnormality, FISH cannot be used for the detection of this alteration. 12 Sequence analysis of the exon harboring the V617 residue has been used to identify the mutation in PV, ET and IM patients, and more recently also in a large collection of CMPDs. 26, 27 More sensitive techniques, such as pyrosequencing and allele specific PCR have significantly increased the number of identified V617F positive patients, and have indicated that most, if not all, PV patients carry this mutation. 9, 26, 35 Future perspectives These studies on the FIP1L1-PDGFRA fusion gene and the JAK2 V617F mutation have once more confirmed that tyrosine kinase defects are a hallmark of CMPDs. In addition, these examples nicely illustrate two different mechanisms to generate a gain-offunction tyrosine kinase in the absence of a cytogenetically visible chromosomal aberration. We can probably expect that genome-wide screening of CMPDs for defects in or around any of the 90 tyrosine kinase genes in the human genome will lead to the identification of novel molecular insights in the pathogenesis of CMPD. The alterations to look for are deletions upstream, downstream of within tyrosine kinase genes, which may result in the generation of fusion genes or just the removal of inhibitory domains of the kinase itself. Second, duplication or amplification of tyrosine kinase genes could also result in the generation of fusion genes. This was recently discovered in T-cell acute lymphoblastic leukemia (T-ALL) with extrachromosomal amplification of ABL1. In these cases, a NUP214-ABL1 fusion gene is generated on the extrachromosomal (episomal) elements. 36, 37 Both deletions and amplifications can be detected using micro-array comparative genomic hybridization (array-CGH). However, we may also not forget that cryptic chromosomal translocations and inversions could also still be undiscovered, as was illustrated by the recent identification of a cryptic t(9;14) resulting in an EML1-ABL1 fusion in T-ALL, 38 and a cryptic inv(7) affecting the HOXA cluster in T-ALL. 39 Finally, point mutations and other subtle nucleotide changes can only be identified by sequencing analysis. Large-scale sequence analysis of all kinase genes has already resulted in the identification of novel tyrosine kinase mutations, including ERBB2 in lung cancer and JAK2 in CMPDs. 12, 40 Are all CMPDs caused by activated protein tyrosine kinases? The answer is no. It was previously shown that rare cases of CML (atypical CML) can be caused by deregulated expression of IL3, 41 and we know that familial forms of polycythemia are caused by mutations in the EPOR, 23 but these are probably nothing more than exceptions that confirm the rule that tyrosine kinases are the important family of oncogenes in CMPDs. The success of imatinib as therapeutic agent for the treatment of CML and CEL with ABL1 or PDGFR rearrangements has demonstrated that the identification of oncogenic tyrosine kinases in CMPDs has important therapeutic consequences. Before imatinib was available, FIP1L1-PDGFRA positive CEL patients displayed a relatively bad prognosis. 17 These patients now show remarkable responses to imatinib treatment with most patients achieving molecular remission, and remain in remission at low doses of imatinib. Molecular characterization of CMPDs has the aim to improve the molecular diagnosis and subclassification of these hematological malignancies, but most importantly, may lead to a significant improvement of their treatment.
